Drug reference

Blinatumomab

Monoclonal Antibody · Antineoplastic

Monoclonal AntibodyAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
BaricitinibSevereDatabaseDDInter
BupropionSevereDatabaseDDInter
CertolizumabSevereDatabaseDDInter

Mechanism

Blinatumomab is a bispecific CD19-directed CD3 T cell engager (BiTE) which causes lysis of B lymphocytes. Its mechanism involves bringing CD3+ T cells and CD19+ leukemia cells into close proximity, enabling T cells to kill the acute lymphoblastic leukemia (ALL) cells.

Indications

Relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukaemia (initiated by a specialist)Philadelphia chromosome-negative acute lymphoblastic leukaemia in complete remission with minimal residual disease (initiated by a specialist)Treatment-refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL)Acute lymphoblastic leukemia (ALL) in remission with minimal residual disease of 0.1% or greaterCD19+ refractory B-lymphoblastic leukemiaacute lymphoblastic leukemia (ALL) including minimal residual disease

Dosing

Adult: BY CONTINUOUS INTRAVENOUS INFUSION: (consult product literature) for relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukaemia. BY CONTINUOUS INTRAVENOUS INFUSION: (consult product literature) for Philadelphia chromosome-negative acute lymphoblastic leukaemia in complete remission with minimal residual disease (body-weight 45 kg and above).
Pediatric: BY CONTINUOUS INTRAVENOUS INFUSION: (consult product literature) for treatment-refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL). BY CONTINUOUS INTRAVENOUS INFUSION: (consult product literature) for ALL in remission with minimal residual disease of 0.1% or greater.
Renal adjustment: Caution is advised in patients with severe renal impairment.
Hepatic adjustment: Caution is advised in patients with severe hepatic impairment.
Geriatric: Limited information available; caution is advised.

Side effects

Common

Abdominal painAnaemiaAphasiaAppetite decreasedArthralgiaChest painChillsCognitive disorderConfusionConstipationCoughDecreased leucocytesDiarrhoeaDizzinessDyspnoea

Serious

Cytokine release syndrome
Neurotoxicity
Neurological events (higher risk in patients with clinically relevant CNS pathology)
Infections
Seizure
neurological toxicities
neutropenic fever
sepsis